Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Crosses Below 200-Day Moving Average – Here’s Why

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)’s share price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $8.32 and traded as low as $5.84. Enanta Pharmaceuticals shares last traded at $5.88, with a volume of 166,938 shares traded.

Analyst Ratings Changes

ENTA has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Robert W. Baird cut their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, November 26th. JMP Securities reiterated a “market outperform” rating and set a $21.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Finally, StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Stock Down 5.2 %

The stock has a 50-day moving average price of $6.36 and a 200 day moving average price of $8.32. The firm has a market capitalization of $125.44 million, a price-to-earnings ratio of -1.19 and a beta of 0.48.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. As a group, equities analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jay R. Luly acquired 45,000 shares of the company’s stock in a transaction dated Wednesday, February 12th. The stock was bought at an average price of $5.69 per share, with a total value of $256,050.00. Following the purchase, the chief executive officer now directly owns 846,638 shares in the company, valued at $4,817,370.22. The trade was a 5.61 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 13.89% of the stock is currently owned by corporate insiders.

Institutional Trading of Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Krensavage Asset Management LLC raised its position in shares of Enanta Pharmaceuticals by 19.7% during the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after buying an additional 246,736 shares in the last quarter. RA Capital Management L.P. bought a new stake in Enanta Pharmaceuticals in the fourth quarter worth approximately $5,968,000. Marshall Wace LLP raised its stake in shares of Enanta Pharmaceuticals by 9.3% in the 4th quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company’s stock valued at $5,348,000 after acquiring an additional 79,197 shares in the last quarter. Millennium Management LLC boosted its holdings in Enanta Pharmaceuticals by 22.7% during the fourth quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company’s stock valued at $5,158,000 after acquiring an additional 165,692 shares during the period. Finally, Geode Capital Management LLC increased its position in Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after acquiring an additional 14,575 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.